Management and prevention of drug resistance in chronic hepatitis B

Liver International

Volumn 29, Issue SUPPL. 1, 2009, Pages 108-115

  Zoulim, Fabien ^a,b,c   Durantel, David ^a,b,c   Deny, Paul ^a,d  

^a INSERM   (France)

^b UNIVERSITÉ LYON 1   (France)

^c HÔTEL DIEU   (France)

^d UNIVERSITÉ PARIS 13   (France)

Author keywords

Antivirals; Drug resistance; Hepatitisb Virus

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; EMTRICITABINE; ENTECAVIR; GENOMIC RNA; HEMOGLOBIN E; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; TELBIVUDINE; TENOFOVIR;

ADD ON THERAPY; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; CONFERENCE PAPER; CROSS RESISTANCE; DOSE RESPONSE; DRUG INDICATION; DRUG SUBSTITUTION; DRUG TARGETING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GENOTYPE; HEMOGLOBIN ANALYSIS; HEPATITIS B; HUMAN; MULTIDRUG RESISTANCE; MUTATIONAL ANALYSIS; NONHUMAN; PHENOTYPE; REAL TIME POLYMERASE CHAIN REACTION; RISK REDUCTION; SALVAGE THERAPY; SEROCONVERSION; VIREMIA; VIRION; VIRUS DETECTION; VIRUS LOAD; VIRUS REPLICATION; VIRUS VIRULENCE;

ANTIVIRAL AGENTS; CLINICAL PROTOCOLS; DRUG RESISTANCE, MULTIPLE, VIRAL; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; VIRUS REPLICATION;

EID: 59149091079     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01939.x     Document Type: Conference Paper

References (47)

1. Zoulim F, Perrillo R. Hepatitis B: Reflections on the current approach to antiviral therapy. J Hepatol 2008; 48 (Suppl.1): S2-19.
2. Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic Hepatitis B virus infection. Antiviral Res 2004; 64: 1-15.
3. Fattovich G. Natural history of hepatitis B. J Hepatol 2003; 39(Suppl. 1): S50-8.
4. Langley DR, Walsh AW, Baldick CJ, et al. Inhibition of hepatitis B virus polymerase by entecavir. J Virol 2007; 81: 3992-4001.
5. Das K, Xiong X, Yang H, et al. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 2001; 75: 4771-9.
6. Litwin S, Toll E, Jilbert AR, Mason WS. The competing roles of virus replication and hepatocyte death rates in the emergence of drug-resistant mutants: Theoretical considerations. J Clin Virol 2005; 34(Suppl. 1): S96-107.
7. Zhang YY, Summers J. Low dynamic state of viral competition in a chronic avian hepadnavirus infection. J Virol 2000; 74: 5257-65.
8. Pawlotsky JM. The concept of hepatitis B virus mutant escape. J Clin Virol 2005; 34(Suppl. 1): S125-9.
9. Zhou T, Saputelli J, Aldrich CE, et al. Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine. Antimicrob Agents Chemother 1999; 43: 1947-54.
10. Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172 * mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008; 48: 88-98.
11. Villet S, Ollivet A, Pichoud C, et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 2007; 46: 531-8.
12. Yim HJ, Hussain M, Liu Y, et al. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006; 44: 703-12.
13. brunelle MN, Jacquard AC, Pichoud C, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005; 41: 1391-8.
14. Villet S, Pichoud C, Villeneuve JP, Trepo C, Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 2006; 131: 1253-61.
15. Pawlotsky JM, Dusheiko G, Hatzakis A, et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 2008; 134: 405-15.
16. Carrouee-Durantel S, Durantel D, Werle-Lapostolle B, et al. Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants. Antivir Ther 2008; 13: 381-8.
17. Chan HL, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir: A randomized trial. Ann Intern Med 2007; 147: 745-54.
18. Di Bisceglie AM, Lai CL, Gane E, et al. Telbivudine globe trial: Maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients. Hepatology 2006; 44(Suppl. 1): 230A (abstract 112).
19. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-51.
20. Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007; 5: 890-7.
21. Zoulim F. New nucleic Acid diagnostic tests in viral hepatitis. Semin Liver Dis 2006; 26: 309-17.
22. Locarnini S, Hatzakis A, Heathcote J, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004; 9: 679-93.
23. Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46: 254-65.
24. Nafa S, Ahmed S, Tavan D, et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by Lamivudine for chronic hepatitis B. Hepatology 2000; 32: 1078-88.
25. Zoulim F. In vitro models for studying hepatitis B virus drug resistance. Semin Liver Dis 2006; 26: 171-80.
26. Zoulim F, Buti M, Lok AS. Antiviral-resistant hepatitis B virus: Can we prevent this monster from growing? J Viral Hepat 2007; 14(Suppl. 1): 29-36.
27. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27: 1670-7.
28. Delaney WET, Ray AS, Yang H, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006; 50: 2471-7.
29. Seigneres B, Pichoud C, Martin P, et al. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology 2002; 36: 710-22.
30. Yang H, Qi X, Sabogal A, et al. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005; 10: 625-33.
31. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004; 48: 3498-507.
32. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292-7.
33. Villeneuve JP, Durantel D, Durantel S, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003; 39: 1085-9.
34. Qi X, Xiong S, Yang H, Miller M, Delaney WET. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 2007; 12: 355-62.
35. Villet S, Pichoud C, Billioud G, et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008; 48: 747-55.
36. Schildgen O, Sirma H, Funk A, et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006; 354: 1807-12.
37. Curtis M, Zhu Y, Borroto-Esoda K. Hepatitis B virus containing the I233V mutation in the polymerase reverse-transcriptase domain remains sensitive to inhibition by Adefovir. J Infect Dis 2007; 196: 1483-6.
38. Sheldon J, Camino N, Rodes B, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005; 10: 727-34.
39. Lampertico P, Vigano M, Manenti E, et al. Low resistance to adefovir combined with Lamivudine: A 3-year study of 145 Lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133: 1445-51.
40. Lampertico P, Vigano M, Manenti E, et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005; 42: 1414-9.
41. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004; 350: 1023-35.
42. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129: 528-36.
43. Sung JJ, Lai JY, Zeuzem S, et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008; 48: 728-35.
44. Hui CK, Zhang HY, Bowden S, et al. 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol 2008; 48: 714-20.
45. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-96.
46. Summers J, Mason WS. Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy. Proc Natl Acad Sci USA 2004; 101: 638-40.
47. Durantel D, Carrouée-Durantel S, Werle-Lapostolle, et al. A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus. Hepatology 2004; 40: 855-64.